Long-term efficacy with deep brain stimulation of the globus pallidus internus in cervical dystonia: a retrospective monocentric study

Clemens Jacksch1*, Kirsten E. Zeuner1, Ann-Kristin Helmers2, Karsten Witt3, Günther Deuschl1 and Steffen Paschen1

Abstract

Background: Cervical dystonia (CD) is characterized by involuntary contractions of the cervical muscles. Data on long-term effectiveness of deep brain stimulation (DBS) are rare. The aim of this study was to evaluate the longitudinal ten years treatment efficacy of DBS in the globus pallidus internus (GPI).

Methods: A retrospective single-center data analysis was performed on patients with idiopathic CD, who were treated with GPI DBS for at least 10 years. TWSTRS severity score and individual sub-items were compared between pre and post DBS surgery (n = 15) over time.

Results: There was a significant and persistent positive effect regarding the severity of TWSTRS between the conditions immediately before and 1, 5, and 10 years after establishment of GPI DBS (mean difference: 6.6–7 ± 1.6). Patients with increasing CD complexity showed a poorer response to established treatment forms, such as injection of botulinum toxin and were thus DBS candidates. Especially a predominant torticollis was significantly improved by DBS.

Conclusion: GPI DBS is an effective procedure especially in severely affected patients with a positive 10-year outcome. It should be considered in more complex CD-forms or predominant torticollis.

Keywords: Idiopathic cervical dystonia, Deep brain stimulation, Long-term effectiveness

Background

Cervical dystonia (CD), as the most common form of adult-onset focal dystonia, is characterized by involuntary contractions of the cervical muscles which lead to abnormous movements or postures [1]. The prevalence varies between a range of 28–183 cases/million with about twice as many women affected as men [2]. Although most forms are idiopathic, “CD mimics” have to be excluded, e.g. vascular, musculoskeletal, infectious or traumatic causes [1, 3]. Clinically CD presents with combinations of head and/or neck rotation, tilt or shift. Tremor may occur as a head or an arm tremor [4]. The severity of CD is objectively assessed either with the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) or the Tsui-score [5–8].

First line therapy is the injection of botulinum toxin (BoNT). Additional treatment possibilities include oral drugs (e.g., anticholinergics). More severely affected patients or those who do not respond sufficiently to the standard treatment may benefit from deep brain stimulation (DBS) of the globus pallidus internus (GPI) [9, 10].
The improvement of dystonic symptoms has a direct influence on health-related quality of life, but 10% of the GPI DBS patients show no response [11].

Long-term data on the effect of GPI stimulation on CD over a longer period are rare. However, single studies were able to provide evidence for a good long-term efficacy with a mean follow-up time of 7.8 and 11.5 years (and an improvement from up to 47.6–54.1% in the TWSTRS severity score). Yet, they are difficult to compare, due to low patient numbers and inconsistent use of scores and endpoints [12, 13]. Other studies provided similar results, but their follow-up periods were either shorter (between 2 and 5 years) [14–17] or the number of patients rather small (n = 4) [18]. A shorter duration of illness [14] and a more phasic than tonic pattern [12] turned out to be possible positive prognostic factors. As a result, some authors suggested neck mobility might be a possible prognostic factor for the preoperative evaluation of suitable patients [19].

In this study, we analyzed the long-term efficacy of GPI-DBS over 10 years and attempted to characterize the CD patients who would particularly benefit from this treatment modality.

Methods
Collection of clinical data
A retrospective single-center data analysis was performed on patients with idiopathic CD, who were treated with GPI-DBS for at least 10 years. We retrieved our data from our electronic patient files and our movement disorder data base. All patients, who were treated in our Movement disorder clinics between 1999 and 2011 were included. Diagnosis was made by two movement disorder specialists in our clinic. Stimulation devices used in patients, who received GPI DBS included models from Medtronic (Activa® PC and RC pulse generator).

The following inclusion and exclusion criteria were applied:

Inclusion criteria
Patients with a confirmed diagnosis of idiopathic cervical dystonia who had a history of GPI DBS for at least 10 years. Patients with dopamine-sensitive cervical dystonia (termed Segawa syndrome) were not considered for analysis. None of our patients used for the analysis were found to have any of the previously known genetic alterations for a possible monogenic inherited dystonia. Also, no patients with a "dystonia plus syndrome" were included, who had another dominant disease feature in addition to dystonia (for example, myoclonus or parkinsonism). However, genetic testing was performed in this group of patients in only a very small proportion, as standard panel testing had not been established at the time of surgery.

All patients must have received regular clinical follow-up visits (at least once a year) with collection of the TWSTRS severity score over this period. If multiple TWSTRS were collected in a time range, the value of the clinical visit closest to the 1, 5, and 10-year treatment period was used. The accepted range to assign the score to a specific time-point was ±3 months in 1-year visit, ±6 months in 5-years visit and ±1 year in 10-years visit.

Exclusion criteria
- stimulation targets other than GPI or stimulation of a second target point (n = 2)
- incomplete follow up data (n = 44)
- parallel treatment with DBS and BoNT (n = 2).

From the 63 CD patients who underwent GPI DBS surgery between 1999 and 2011, 15 patients with CD and fulfilled inclusion criteria remained.

To avoid potential confounders, patients with parallel botulinum toxin treatment were excluded. The reasons why these patients received BoNT in parallel were a poor response to the GPI DBS (poor responder) and concomitant pain. There are various reasons why patients did not show up for their scheduled clinical visits. As a reference center, we carry out many DBS surgeries every year, but the follow-up care of a considerable number of patients takes place close to their place of residence in other neurological clinics, which offer the follow-up care but not the surgery itself. In addition, those patients for whom the TWSTRS was not collected during the clinical visits or for whom the recordings could not be retrospectively reconstructed also dropped out of the analysis.

The Consort patient flow in Fig. 1 gives an overview of the study population.

For objective monitoring of disease severity, we used the TWSTRS severity score, which is our standard assessment during regular clinical visits.

The TWSTRS, as our validated rating scale, includes subitems for motor function, disability, and pain. The motor part, as we used in this study, has 0–35 points, the disability part 0 to 30 points and the pain part 0–20 points, with higher values indicating more severe symptoms. The TWSTRS-severity estimates the clinical CD presentation (torticollis, laterocollis, anterocollis, retrocollis, duration, shoulder elevation, range of voluntary rotational head movement, sensory trick).

The TWSTRS severity score recorded during clinical visits was compared over time between the different time
points. An improvement of at least 25% on the TWSTRS was considered as a clinically relevant response [11].

Furthermore, we conducted a sub-analysis to compare sub-items of the TWSTRS severity score before and after DBS surgery in a group of eleven patient, who had been treated with BoNT long term in our hospital prior to surgery.

**Statistical analysis**

The data were analyzed with the freely available program "JASP" (version 0.14, University of Amsterdam, Amsterdam, The Netherlands). In addition to the descriptive data analysis, repeated measures ANOVA with accompanying Greenhouse–Geisser correction and post-hoc testing at the 5% level were implemented to determine the long-term effect. P values < 0.05 were considered statistically significant. To examine a significant difference regarding the individual TWSTRS sub-items, paired t-tests were performed. The literature search with pubmed used the keywords "idiopathic cervical dystonia", "deep brain stimulation", "botulinum toxin" and "long-term effectiveness".
Results

Descriptive

The clinical baseline characteristics of the study population are shown in Table 1. The patients treated with GPI DBS had a mean age of 61.5 years, a slight dominance of the female sex (53.3%) and a mean disease duration of 26.6 years. Interestingly, both the amplitude (2.8/3.05 V), frequency (143.3/139.3 Hz) and pulse width (93/92 µs) used remained relatively constant over the years.

Possible stimulation-induced side effects most frequently included the occurrence of dysarthria (5/15) and parkinsonoid (2/15). In addition, two cases required surgical revision due to cable traction and one infection in the area of the pulse generator necessitating its replacement.

Patients who never had a satisfactory result with BoNT prior to surgery were considered as primary non-responders (defined as a reduction of the severity score of 2 points or less after the first or second BoNT injection). Secondary non-responders included those patients, who had obtained at least 2 successful injections of BoNT (assuming a reduction of the severity score by at least 3 points and/ or adequate weakness of the injected muscles) [20].

Long-term efficacy

Descriptive data analysis already suggested a higher pre-DBS TWSTRS severity score compared with 1, 5, and 10 years after surgery. Repeated measures ANOVA reported a significant decline (p < 0.001) after Bonferroni correction that remained stable over 1, 5 and 10 years (mean difference 6.6–7.0 points ±1.6 when comparing pre-DBS TWSTRS with assessments 1, 5 and 10 years of ongoing GPI DBS). The course of TWSTRS severity score in the DBS group over the 10-year period is illustrated in Fig. 2.

Of the 15 patients studied, one patient was a DBS "non-responder" (TWSTRS before and 10 years after surgery 24 and 25 points, respectively). This corresponds to a rate of approximately 6.7%, 93.3% of patients responded well for 10 years. A valid response rate cannot be given based on the available case numbers. In larger randomized studies, the response rate was more than 80% after 5 years [20].

Interestingly, the effect of GPI DBS coincides relatively well with the benefit from botulinum toxin injection known from the current literature (ΔGPI DBS: 6.6–7.0 ± 1.6; ΔBoNT: 6.4–6.6 [21]) as measured by the TWSTRS severity score.

Clinical course in patients changing from BoNT to GPI DBS

Of the 15 patients in the GPI DBS group, eleven received BoNT therapy in our outpatient clinic prior to DBS surgery. From the remaining 4 patients, no documentation of BoNT treatment was available for 3 patients (referral from an external clinic), one patient suffered from myasthenia gravis and was thus not eligible for BoNT. The mean BoNT-treatment time was 10 years (min. 1 year; max. 20 years). All of them showed increasing complexity of their dystonic symptoms during the preoperative period. Especially these patients with increasing complexity and a predominant torticollis made the decision in favor for DBS. Table 2 shows exemplary the disease courses in 4 of the 11 patients. This should illustrate how CD can become more complex over years. More complex dystonia was defined as follows: (i) an increase in motor score as measured with the TWSTRS; (ii) additional dystonic features (for example laterocollis/retrocollis/antero-collis in addition to torticollis; torticollis in addition to previously retrocollis or laterocollis etc.); (iii) The dystonic presentation increased in severity (for example torticollis started initially with 30° and worsened to >45°, or a laterocollis presented with 10°, and increased to 30°).

In addition, higher complexity may also be related to poorer treatability of CD by BoNT, despite an initial usually good response.

In interpreting the different clinical courses, a dystonic (head) tremor could be suspected as a possible additional reason for the decision to GPI DBS, which is not captured in the TWSTRS.

7 of 15 patients had concomitant dystonic head tremor, which improved good to excellent in five patients. One patient had a subjective worsening after DBS surgery and one patient had a constant finding in regard to the tremor.

A sub-analysis of the DBS effect on the TWSTRS and its subitems of these 11 patients was conducted. Since BoNT is the standard treatment and in most cases initially applied to most of the patients, we intended to present the DBS effect in this subgroup. There was a significant and clinical meaningful decreasing in TWSTRS of 27.4% after one year of GPI DBS. Thus, this was comparable to the effect of the overall group.

We applied another paired t-test to compute the DBS-effect on the individual TWSTRS-subitems in this subgroup of patients. There was a statistically significant improvement of torticollis 12 months after surgery by an average of 1.1 points (56%; p = 0.021). In other words, an improvement of 1.1 points means a torticollis reduction
Table 1 Clinical features of CD patients and long-term treatment with GPI DBS

| No. | Sex/Age | CD length (years) | DBS surgery in xx year of disease | BoNT pre-treated in our clinic | 1°/2°. non-response to BoNT | Mode | Amplitude year 1/10 after DBS surgery (V) | Frequency year 1/10 after DBS surgery (Hz) | Pulse width year 1/10 after DBS surgery (µs) | ADM |
|-----|---------|-------------------|-----------------------------------|-------------------------------|-----------------------------|------|------------------------------------------|--------------------------------------------|-------------------------------------------|-----|
| 1   | Female/60 | 19                | 13                                | Yes                           | 2°                          | DM   | 3.0/3.0                                  | 180/125                                  | 90/90                                     | None |
| 2   | Male/61   | 17                | 4                                 | Yes                           | 2°                          | M    | 2.5/2.2                                  | 130/180                                  | 90/90                                     | None |
| 3   | Male/54   | 22                | 9                                 | Yes                           | 2°                          | M    | 2.7/3.9                                  | 130/130                                  | 120/90                                    | BA  |
| 4   | Female/58 | 9                 | 1                                 | Yes                           | 1°                          | IL   | 2.8/3.8                                  | 130/125                                  | 90/90                                     | None |
| 5   | Male/70   | 50                | 38                                | Yes                           | 2°                          | M    | 2.6/2.7                                  | 130/130                                  | 90/90                                     | BA  |
| 6   | Female/56 | 11                | 6                                 | No                            | –                           | M    | 4.0/40                                   | 130/130                                  | 120/90                                    | None |
| 7   | Male/55   | 21                | 6                                 | No                            | –                           | M    | 3.45/3.3                                 | 180/180                                  | 105/120                                   | None |
| 8   | Female/67 | 41                | 33                                | Yes                           | 2°                          | DM   | 2.25/2.35                                | 130/130                                  | 60/60                                     | None |
| 9   | Male/68   | 26                | 20                                | Yes                           | 2°                          | M    | 3.25/3.05                                | 180/180                                  | 120/120                                   | None |
| 10  | Male/70   | 50                | 36                                | Yes                           | 2°                          | M    | 2.5/2.6                                  | 130/130                                  | 90/90                                     | None |
| 11  | Female/44 | 24                | 10                                | Yes                           | 2°                          | M    | 3.25/3.25                                | 180/130                                  | 90/120                                    | None |
| 12  | Male/58   | 35                | 19                                | No                            | –                           | DM   | 2.0/1.4                                  | 130/130                                  | 60/60                                     | None |
| 13  | Female/53 | 22                | 10                                | Yes                           | 2°                          | M    | 2.5/2.7                                  | 130/130                                  | 90/90                                     | None |
| 14  | Female/63 | Unknown           | Unknown                           | Yes                           | 1°                          | M    | 1.8/3.8                                  | 130/130                                  | 60/60                                     | None |
| 15  | Female/85 | 26                | 11                                | No                            | –                           | M    | 3.8/3.75                                 | 130/130                                  | 120/120                                   | None |
| Mean±SD | Female: 53.3% | 26.6 (9, 50) | 15.4 (1, 38) | Yes: 73.33% | 2°: 81.8% | M: 73.3% (DM: 20%, IL: 6.7%) | 2.8/3.05 | 143/139.3 | 93/92 | BA: 2 |

ADM: additional anti dystonic medication; DM: double monopolar; M: monopolar; BA: beta agonist; IL: interleaving
of 22° according to the TWSTRS. The range of voluntary head motion showed a trend ($p = 0.05$) to an improvement of approximately 60% (mean difference 0.67 points). Further sub-items revealed no significant differences. The tendency, however, was in favor for an improvement in a pre-existing shoulder elevation from up to 45.6%, as well as an improvement in an anterocollis and retrocollis (-16.5%) (compare Table 3).

| Patients characteristics (sex/age) | Initial finding | Development during long-term BoNT | Just before DBS surgery | Change after DBS surgery |
|-----------------------------------|----------------|-----------------------------------|-------------------------|-------------------------|
| w, 60                             | “no-no” tremor, phasic/myo-cloniform dystonic activity of the left shoulder; TWSTRS 14 | Initially in 5-year course good response with only mild TC; TWSTRS 9 | After approx. 10 years pronounced TC as well as RC and LC; TWSTRS 18 | Tremor markedly improved, only subtle TC and LC, no RC described; TWSTRS 13 |
| m, 68                             | Moderate-sever dystonia with predominant AC (30°) and TC (30°) | Relatively stable course, new LC (pre BoNT 60°), post BoNT 30°, TC and AC at the same level as before; TWSTRS 10 | In particular, increase in LC and pronounced shoulder elevation, TWSTRS 26 points. Severe effect on neck pain | Improvement of all individual components, TWSTRS 18 points, favorable effect on pain |
| m, 56                             | Moderate TC (30°) and light LC (15°), also moderately severe shoulder elevation; TWSTRS 16 points | Mainly stable course, TWSTRS after 7 years 16 points | Higher complexity with increase in LC to 16°–35°, newly added AC with retrocaput, TWSTRS 20 points | Improvement with now still slight TC (20°) and LC (15°), TWSTRS 16 points |
| w, 61                             | Moderate cervical dystonia with TC (20°) and LC (20°), TWSTRS 11 points | Deterioration of TC to 45°–67° | Further deterioration in TC to 68°–90°, TWSTRS 23 points | Continued moderate-severe TC (45°–67°), also slight lateral shift and problems crossing the midline, TWSTRS 18 points |

TWSTRS: Toronto Western Spasmodic Torticollis Rating Scale; TC: Torticollis; RC: Retrocollis; LC: Laterocollis; AC: Anterocollis

**Discussion**

Our open, retrospective study demonstrates good long-term efficacy of GPI DBS using a valid questionnaire in patients with CD over a 10-year period.

We confirmed (A) a positive effect of GPI DBS over at least a decade. Considering different disease courses, we (B) defined a subgroup of CD patients who worsened after long-term BoNT treatment and were thus candidates for GPI DBS. These were primarily patients with more complex CD-pattern and predominant torticollis. The baseline TWSTRS severity score was higher in this group than in groups investigated with regard to the long-term BoNT effect [21]. Comparing individual subitems of the TWSTRS severity score, we (C) showed significant improvement in torticollis ($−56\%$, $p = 0.021$) and displayed a favorable trend for the range of voluntary rotational head movement ($−60\%$, $p = 0.05$).

Our results are discussed in detail below:

The significant reduction in CD-severity with GPI DBS between 6.6 and 7.0 points ($p < 0.001$) on TWSTRS severity score is comparable to the well-known maximum effect after injection of BoNT [21, 22]. The positive effect remained stable over a 10-year period.

Recent studies reported on similar long-lasting effects of botulinum toxin up to 27 years [15].

The observed decrease in the TWSTRS severity score after implementing GPI DBS corresponds to a relative reduction of 29.1–30.8% and is in range with the BoNT treatment efficacy of larger cohorts. For example, Benecke et al. [21] showed in 463 patients with recurrent BoNT treatment an improvement in the TWSTRS severity score between 6.4 and 6.6 points (relative reduction of 38.1%) at 16-week follow-up. Comella et al. [22] demonstrated a decrease of 23% (reduction of 3.7 points...
in TWSTRS severity score 4 weeks after injection) in a group of 139 BoNT-treated CD patients.

The improvement after GPI DBS in the TWSTRS severity score in our study is similar to previous reports (e.g. 27.8% in Loher et al. [18]). However, some research groups found even higher improvements as described by Walsh et al. [13] (51.4%) or Cacciola et al. [16] (66.6%). In contrast to this study, the latter two showed a smaller number of patients included (n=10) and a shorter follow-up time (37.6 months [16] and 7.8 years [13]). This might be a possible explanation for the different rates of improvement.

To our knowledge, this study is the largest CD cohort with continuous follow-up over 10 years demonstrating a positive effect of GPI DBS. In contrast, study populations of 4 [18], 8 [14, 23], and 10 [13, 15, 16] numbers are reported, with mean follow-up ranging from 30 [23] to 93.6 months [13].

The shown improvement of at least 25% is generally considered clinically significant, as described in larger previous studies of GPI DBS [11, 17]. However, the data on the efficacy of GPI DBS varies considerably. Several reasons could be given for this. On the one hand, stimulation parameters used varies widely and on the other hand patient populations are diverse with highly different observation times. For instance, the average pulse width used ranged from low (71 µs [15]) to exceptionally high (450 µs [14]) values. In our clinical experience, particularly high values are often accompanied by merely tolerated side effects such as dysarthria or ataxia. These side effects are generally attributed to a stimulation effect of the internal capsule [24]. However, currently the optimal pulse width for best stimulation effect remains unclear [25].

Now, we discuss the already mentioned eleven patients who received DBS surgery after previous long-term BoNT treatment in our clinic. Each of them had been pretreated with BoNT for at least 10 years. The relative reduction in the TWSTRS severity score one year after implementing GPI DBS was 27.4%. According to our prior determination, this decrease must be considered as clinically meaningful with a positive impact on health-related quality of life [11]. There seems to be a beneficial effect of GPI stimulation beyond BoNT in selected cases. One main reason to undergo DBS surgery could be an increasing complexity of CD over time, as described in up to 17% of patients treated with BoNT [23]. Due to the more complex presentation, probably the BoNT injections pattern became more difficult with a subsequent unsatisfactory treatment response or not tolerated side effects such as dysphagia. This assumption is supported by higher baseline TWSTRS severity scores in patients before GPI DBS compared to those who show a stable effect on BoNT. The presurgical TWSTRS severity score averaged 22.7 points, which is comparable to other studies (e.g. 21.5 points, Walsh et al. [13]). In comparison, other groups who investigated the efficacy of BoNT reported a lower mean severity score, e.g. 18 points by Benecke et al. [25].

Regarding CD-phenomenology, torticollis (90–100%), laterocollis (64–67%) and tremor (55–60%) were the most prominent clinical features. The high frequency of torticollis and tremor have been described previously [13, 30].

It is conceivable that certain predictors can be identified for patients, who might benefit from early DBS surgery.

For example, considering the different TWSTRS subitems, we found particularly a positive effect on torticollis and a statistical trend for improvement of the range of voluntary rotational head movement (p=0.05). This appears to be important because the range of neck mobility is considered as a potential prognostic marker for GPI stimulation efficacy [19]. Torticollis is the most common presentation of cervical dystonia [16] and seems to be an important reason for patients to decide to undergo surgery. Furthermore, as exemplified in Table 2, even torticollis that initially responds well to BoNT can worsen over the years. In the analysis, a clearly significant reduction was evident with regard to torticollis in the comparison of all TWSTRS subitems. In view of the fact that torticollis is the most frequent single manifestation of CD, DBS seems to be particularly effective here.

In addition, a dystonic head tremor that cannot be sufficiently treated with BoNT injections seems to be another strong indication for DBS surgery. The majority of patients with tremor examined here showed a good treatment effect.

Finally, troublesome antecollis, which is often difficult to treat with BoNT, could be another argument in favor of GPI DBS. For example, a bilateral injection of the scaleni muscles contains a risk for dysphagia and the improvement is unsatisfactory in most cases. As shown in Table 3, there is a good response with a reduction in AC of 16.5% (and just missed significance at p = 0.051).

Relevant for patients are the number of clinical visits for sustained treatment effects. Typically, BoNT injections are given every 12 weeks, or approximately 4 times per year. In our clinic, the first postoperative visit after DBS implementation takes place 3 months after surgery and then usually semi-annually or annually. Thus, with regard to postoperative management, a reduction of clinical visits compared to BoNT of 50–75% can be expected here. However, if relevant side effects occur, the number of annual DBS visits can of
course increase. The maximum number of visits was reached in a patient with stimulation-induced parkinsonoid (average 3 times per year).

Conclusion
The strength of our work is based on the demonstration of the 10-year efficacy of GPI DBS, which also allows a comparison with the known long-term effectiveness of the primary indicated treatment form botulinum toxin. Limitations of our work include the retrospective design. Furthermore, other relevant aspects of cervical dystonia such as pain or dystonic head tremor are not considered in the TWSTRS severity score. Nevertheless, there is already a good data base that a reduced motor score in the TWSTRS can lead to a reduction in pain as well as improvement in quality of life [17]. Moreover, comparisons between DBS and BoNT will continue to be difficult, as the assessment of the effect of BoNT injection is limited by the time course (onset of the maximum effect after a few weeks) and the dependence on the treating physician.

Future long-term studies are required to better characterize the different clinical courses of CD during the various treatment modalities to define the most effective therapy for each individual patient.

In summary there is a positive long-lasting effect of GPI DBS in CD. A particularly good response to GPI DBS was observed in patients with poor primary or secondary response to BoNT. Those patients suffered mainly from more complex forms of CD and often showed predominant torticollis.

Abbreviations
CD: Cervical dystonia; DBS: Deep brain stimulation; GPI: Globus pallidus internus; TWSTRS: Toronto Western Spasmodic Torticollis Rating Scale; BoNT: Botulinum toxin.

Acknowledgements
We thank Prof. Dr. Jens Volkmann (University Hospital Würzburg) for his accurate collection of the disease scores.

Author contributions
CI was involved in the conception, organization and execution of the present study. He also performed the statistical data analysis and wrote the first draft of the manuscript. KE and SP were also involved in the conception and organization of the study and in planning the statistical data analysis. AKH, KW and GD were available for review and critique of the present work. All authors read and approved the final manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was approved by the local Ethics Committee of the Christian Albrechts University of Kiel (AZ: DS96/21). Informed patient consent was not necessary for this work. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Consent for publication
Not applicable.

Competing interests
CI declares that he has no competing interests. KEZ has received research support from Strathmann. She reports speaker’s honoraria from Bayer Vital GmbH, BIAL, AbbVie Allergan and Merz outside the submitted work. She has served as a consultant and received fees from Merz, Ipsen, Alexion and the German Federal Institute for Drugs and Medical Devices (BfArM). AKH has received financial research support by the DFG (SFB 1261) and lecture fees from Medtronic. KW serves as a consultant for BIAL and is a member of advisory boards of Biogen and Stadapharm. He receives royalties form Thieme publishers and Elsevier. GD has served as a consultant for Boston Scientific, Aleva, Cavion and Functional Neuromodulation. He has received lecture fees from Boston Scientific and royalties from Thieme publishers. He is a government employee and receives funding for his research through his institution from the German Research Council, the German Ministry of Education and Research and Medtronic. SP has received lecture fees from Medtronic, Insightec and Boston Scientific, travel grants from Destin and AbbVie, educational grants from AbbVie and Boston Scientific.

Author details

Department of Neurology, Christian Albrechts-University of Kiel, Arnold-Heller-Str. 3, 24105 Kiel, Germany. 2Department of Neurosurgery, Christian Albrechts-University of Kiel, Kiel, Germany. 3Department of Neurology and Research Center Neurosensory Science, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.

Received: 24 June 2022   Accepted: 12 August 2022

References
1. Albanese, A., Bhatia, K., Bressman, S. B., DeLong, M. R., Fahn, S., Fung, V. S., C., Hallett, M., Jankovic, J., Jinnah, H. A., Klein, C., Lang, A. E., Mink, J. W., & Teller, J. K. (2013). Phenomenology and classification of dystonia: A consensus update. Dystonia: Phenomenology and classification: Movement Disorders, 28(7), 863–873. https://doi.org/10.1002/mds.25475
2. Defazio, G., Jankovic, J., Giel, J. L., & Papapetropoulos, S. (2013). Descriptive epidemiology of cervical dystonia. Tremor and Other Hyperkinetic Movements, 3, 03. https://doi.org/10.5343/tomh.170
3. Raju, S., Ravi, A., & Prashanth, L. (2019). Cervical Dystonia Mimics: A Case Series and Review of the Literature. Tremor and Other Hyperkinetic Movements, 9(0), Article 0. https://doi.org/10.5343/tomh.465
4. Reichel, G., Stenner, A., & Jahn, A. (2009). Zur Phänomenologie der zervikalen Dystonien. Fortschritte der Neurologie-Psychiatrie, 77(5), 272–277.
5. Comella, C. L., Leurgans, S., Wuu, J., Stebbins, G. T., The Dystonia Study Group. (2003). Rating scales for dystonia: A multicenter assessment. Movement Disorders, 18(3), 303–312. https://doi.org/10.1002/mds.10377
6. Jost, W. H., Heefter, H., Stenner, A., & Reichel, G. (2013). Rating scales for cervical dystonia: A critical evaluation of tools for outcome assessment of botulinum toxin therapy. Journal of Neural Transmission, 120(3), 487–496. https://doi.org/10.1007/s00702-012-0887-7
7. Tsui, J. K., Eisen, A., Stroessl, A. J., Calne, S., & Calne, D. B. (1986). Double-blind study of botulinum toxin in spasmodic torticollis. Lancet, 2(8501), 245–247. https://doi.org/10.1016/0140-6736(86)92070-2
8. Tsui, J. K., Eisen, A., Mak, E., Carruthers, J., Scott, A., & Calne, D. B. (1985). A pilot study on the use of botulinum toxin in spasmodic torticollis. Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques, 12(4), 314–316. https://doi.org/10.1007/BF0071167100354 0X
9. Jinnah, H. A. (2020). Medical and surgical treatments for dystonia. Neurology, 38(2), 325–348. https://doi.org/10.1017/njd.2020.001.003
10. Termsarasab, P., Thammongkolchai, T., & Frucht, S. J. (2016). Medical treatment of dystonia. Journal of Clinical Movement Disorders, 3(1), 19. https://doi.org/10.1186/s40734-016-0047-6
11. Volkmann, J., Wolters, A., Kupisch, A., Müller, J., Kühn, A. A., Schneider, G.-H., Poeoe, W., Hering, S., Eisnet, W., Müller, J.-U., Deutschl, G., Pinsker, M. O., Skogseid, I.-M., Roeste, G. K., Krause, M., Tronnier, V., Schnitzler, A., Voges, J., Nkhkhah, G., & Benecke, R. (2012). Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. The Lancet Neurology, 11(12), 1029–1038. https://doi.org/10.1016/S1474-4422(12)70257-0
12. Kaelin-Lang, A., You, H., Burgunder, J.-M., Lönfrons-Weitzte, T., Hoher, T. J., Taub, E., Isaias, I. U., Krauss, J. K., & Michael Schüpbach, W. M. (2020). Bilateral pallidal stimulation improves cervical dystonia for more than a decade. Parkinsonism & Related Disorders, 81, 78–81. https://doi.org/10.1016/j.parkreldis.2020.10.028
13. Walsh, R. A., Sidiroopoulos, C., Lozano, A. M., Hodaie, M., Poon, Y.-Y., Fallis, M., & Moro, E. (2013). Bilateral pallidal stimulation in cervical dystonia: Blinded evidence of benefit beyond 5 years. Brain, 136(3), 761–769. https://doi.org/10.1093/brain/awt009
14. Yamada, K., Hamasaki, T., Hasegawa, Y., & Kuratsu, J. (2013). Long disease duration interferes with therapeutic effect of globus pallidus internus pallidal stimulation in primary cervical dystonia: Disease duration and Gpi stimulation in CD. Neuromodulation: Technology at the Neural Interface, 16(3), 219–225. https://doi.org/10.1111/j.1525-1403.2012.00464.x
15. Hung, S. W., Hamani, C., Lozano, A. M., Poon, Y.-Y., Fan, W., the Dystonia Study Group. (2005). Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology, 65(9), 1423–1429. https://doi.org/10.1212/01.wnl.0000183055.81056.5c
16. Kessler, K. R., Skutta, M., & Benecke, R. (1999). Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency. Journal of Neurology, 246(4), 265–274. https://doi.org/10.1007/s004150050345
17. Bonecchi, R., Jost, W. H., Kanovsky, P., Rubin, M., Sidiropoulos, C., & Grafe, S. (2005). A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology, 64(11), 1949–1951.
18. Comella, C. L., Jankovic, J., Shannon, K. M., Tsui, J., Swenson, M., Leurgans, S., Fan, W., the Dystonia Study Group. (2005). Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology, 65(9), 1423–1429. https://doi.org/10.1212/01.wnl.0000183055.81056.5c
19. Skogseid, I. M., & Kerty, E. (2005). The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. European Journal of Neurology, 12(3), 163–170. https://doi.org/10.1111/j.1468-1331.2004.01035.x
20. Kessler, K. R., Skutta, M., & Benecke, R. (1999). Long-term treatment of cervical dystonia with botulinum toxin A. Efficiency, safety, and antibody frequency. Journal of Neurology, 246(4), 265–274. https://doi.org/10.1007/s004150050345
21. Bonecchi, R., Jost, W. H., Kanovsky, P., Rubin, M., Sidiropoulos, C., & Grafe, S. (2005). A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology, 64(11), 1949–1951.
22. Comella, C. L., Jankovic, J., Shannon, K. M., Tsui, J., Swenson, M., Leurgans, S., Fan, W., the Dystonia Study Group. (2005). Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology, 65(9), 1423–1429. https://doi.org/10.1212/01.wnl.0000183055.81056.5c
23. Bonecchi, R., & Grafe, S. (2005). The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. European Journal of Neurology, 12(3), 163–170. https://doi.org/10.1111/j.1468-1331.2004.01035.x
24. Koeglberger, T., Palleis, C., Hell, F., Mehrkens, J. H., & Bötz, K. (2019). Deep brain stimulation programming for movement disorders: Current concepts and evidence-based strategies. Frontiers in Neurology, 10, 410. https://doi.org/10.3389/fneur.2019.00410
25. Mulroy, E., Vrijeratnam, N., De Roquemurea, S., Bhatia, K. P., Zinnoz, L., Foltynie, T., & Limousin, P. (2021). A practical guide to troubleshooting pallidal deep brain stimulation issues in patients with dystonia. Parkinsonism & Related Disorders, 87, 142–154. https://doi.org/10.1016/j.parkreldis.2021.05.017